UTILITY OF PET USING 18FLUORO-3-DEOXY-L-FLUOROTHYMIDINE (FLT-PET) IN LYMPHOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 功能成像这一术语指的是一种技术，它允许成像不像CT扫描那样基于组织和器官的大小和形状，而是基于这些组织中细胞的功能特性。例如，使用18-氟-2-脱氧葡萄糖(FDG)的正电子发射断层扫描(PET)基于新陈代谢成像组织，在高速率代谢葡萄糖的细胞中具有高摄取示踪剂的能力。FDG-PET在许多癌症患者的护理中很有用，包括淋巴瘤。然而，它在某些特定情况下存在缺陷，例如确定淋巴瘤的分级或侵袭性，以及将淋巴瘤与感染或炎症等非癌症病变区分开来。18-氟-3‘-脱氧-3’-L-氟胸苷(Flt)是一种通过细胞主动分裂摄取的新型示踪剂。已有研究表明，与FDG相比，Flt在判断肿瘤分级和鉴别肿瘤与炎症方面可能更好。 我们建议进行一项先导性研究，以观察不同类型淋巴瘤患者的Flt-PET成像特征。我们的目标包括：a)确定Flt-PET扫描是否能发现不同类型淋巴瘤患者的癌病变；b)确定PET确定的Flt摄取强度及其与淋巴瘤分级是否相关；c)比较Flt-PET和FDG-PET在检测不同类型淋巴瘤的癌病变方面的差异。‘

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The term functional imaging refers to technology that allows imaging not based on sizes and shapes of tissues and organs, as in CT scanning, but rather based on functional properties of the cells in these tissues. For example, positron emission tomography (PET) using 18-fluoro-2-deoxyglucose (FDG) images tissues based on metabolism, with high uptake of tracer in cells that metabolize glucose at a high rate. FDG-PET is useful in the care of patients with many cancers, including lymphoma. However, it presents drawbacks in some specific situations, such as determining grade, or aggressiveness, of lymphoma, as well as differentiating lymphoma from non-cancerous lesions such as infection or inflammation. 18-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT) is a new tracer which is taken up by actively dividing cells. It has been suggested that FLT might be better in determining grade and differentiating cancer from inflammation than is FDG. We propose a pilot study to look at the characteristics of FLT-PET imaging in patients with various types of lymphoma. Our objectives include a) to determine whether FLT-PET scanning detects cancerous lesions in patients with various types of lymphoma, b) to determine intensity of FLT uptake as determined by PET and whether it correlates with lymphoma grade, and c) to compare FLT-PET to FDG-PET in detection of cancerous lesions in diverse types of lymphoma.'